The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis

(2015) Clayton English et al.   CLINICAL THERAPEUTICS

Disease-modifying treatments for multiple sclerosis - a review of approved medications

(2015) Ø. Torkildsen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Role of the innate and adaptive immune responses in the course of multiple sclerosis

(2015) Bernhard Hemmer et al.   LANCET NEUROLOGY

Multiple Sclerosis: Current Knowledge and Future Outlook

(2014) Christian P. Kamm et al.   EUROPEAN NEUROLOGY

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial

(2014) Luca Massacesi et al.   PLoS One

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

(2013) Gilles Edan et al.   CNS DRUGS

Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis

(2012) James M. Stankiewicz et al.   Neurotherapeutics

Multiple sclerosis in Italy: cost-of-illness study

(2011) F. Patti et al.   NEUROLOGICAL SCIENCES

Age and disability accumulation in multiple sclerosis

(2011) A. Scalfari et al.   NEUROLOGY

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

(2010) E. Kingwell et al.   NEUROLOGY